Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasiglifam vs Sitagliptin with Metformin in T2DM
NCT01834274Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jun 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of fasiglifam in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Glycosylated Hemoglobin at 24 weeks. Started Jun 2013; status: terminated.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01834274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834274.